Dennis Phillip Andrew, Chief Medical Officer of NovaBridge Biosciences, filed a Form 4 on September 21, 2026, disclosing the vesting of restricted share units and a subsequent sale of ordinary shares on September 17 and 18, 2026.

Key Highlights

  • RSU Vesting: 10,302 restricted share units (representing 10,302 ADSs) were converted to ordinary shares on September 17, 2026, via transaction code M.
  • Shares Acquired: The vesting resulted in 23,695 ordinary shares acquired, represented by 10,302 ADSs, at a price of $0 for the derivative security.
  • Shares Sold: On September 18, 2026, 8,209 ordinary shares (represented by 3,569 ADSs) were disposed of at a converted sales price of $0.71 per ordinary share, equivalent to $1.6247 per ADS.
  • Post-Transaction Ownership: Following the reported transactions, Andrew directly holds 173,427 ordinary shares (represented by 75,403 ADSs) and 72,120 RSUs (in ADS form).
  • Original RSU Grant: The RSUs originated from a grant of 164,840 RSUs on June 17, 2024, vesting over four years, with one-fourth on the first anniversary and the balance ratably over the subsequent 12 quarters.
  • ADS Conversion Ratio: Each 10 ADSs represent 23 ordinary shares of the issuer, according to the filing.

NovaBridge Biosciences CMO Andrew Discloses RSU Conversion and Open-Market Share Sale

According to the Form 4 filed with the SEC on September 21, 2026, Dennis Phillip Andrew, serving as Chief Medical Officer of NovaBridge Biosciences (NASDAQ:NBP), reported two transactions in the company's ordinary shares across consecutive days in September 2026. The filing covers activity dated September 17 and September 18, 2026, and was signed by Kyler Lei as Attorney-in-Fact.

On September 17, 2026, Andrew acquired 23,695 ordinary shares through the vesting (transaction code M) of 10,302 restricted share units, each of which represented a contingent right to receive one ADS. The filing notes that these RSUs originated from a grant of 164,840 units made on June 17, 2024, structured to vest over four years: one-fourth on the first anniversary of the grant date, with the remaining balance vesting ratably over the subsequent 12 quarters on the 17th day of each third month. Following this vesting event, Andrew's directly held ordinary shares stood at 181,636, represented by 78,972 ADSs, according to the filing.

On September 18, 2026, Andrew disposed of 8,209 ordinary shares (represented by 3,569 ADSs) at a reported price of $0.71 per ordinary share. The filing states this figure represents the converted sales price of the ADSs of $1.6247 per ADS. After this sale, the filing reports Andrew's direct beneficial ownership at 173,427 ordinary shares, represented by 75,403 ADSs, along with 72,120 remaining RSUs held in ADS form.

What Was Disclosed

The filing reports an RSU vesting of 10,302 units into 23,695 ordinary shares on September 17, 2026, followed by a sale of 8,209 ordinary shares at $0.71 per share on September 18, 2026, leaving Andrew with 173,427 ordinary shares and 72,120 RSUs directly held.